23andMe Investor Day Presentation Deck
Executive Summary - Therapeutics
23andMe has generated a research and development pipeline covering multiple
therapeutic areas in indications of high unmet medical need
• To date, more than 40 programs have been generated from the database as part of our
collaboration with GSK
GSK has extended their exclusive target discovery period of their collaboration with
23andMe for an additional fifth year
• 23andMe advanced a novel immuno-oncology antibody targeting CD200R1,
23ME-00610, into the clinic
• 23andMe has taken a royalty option on immuno-oncology antibody collaboration
program targeting CD96 into later stages of development
• Managing our therapeutic portfolio investments based on scientific data to optimize
investment, mitigate risk and maximize potential future returns
Copyright © 2022 23andMe, Inc.
23andMe
54View entire presentation